Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 823-lymphoma-and-non-acute-leukemia-with-other-procedures-with-mcc
    Ask Trek AI about this page

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    DRG 823 applies to inpatient hospitalizations for lymphoma and non-acute leukemia when other significant procedures are performed and a Major Complication or Comorbidity is present. This Diagnosis-Related Group reflects higher resource use and influences Medicare inpatient reimbursement by assigning a higher payment weight for cases with major complications and additional procedures.

    Customize your policy alerts

    Sign up for drg 823 policy alerts

    Get alerted when payer policies referencing 823 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 823 Overview

    DRG 823 covers inpatient stays for patients with lymphoma and non-acute leukemia who undergo other significant procedures and have a Major Complication or Comorbidity. This category captures higher-resource hospitalizations where additional operative or procedural care substantially affects costs. It is important for Medicare payment because the presence of a Major Complication or Comorbidity and qualifying procedures increase reimbursement relative to less complex groups. Accurate coding of principal diagnosis, procedures, and complications determines assignment to this Diagnosis-Related Group and the associated payment weight.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Studies of intensive inpatient chemotherapy regimens and supportive-care bundles for patients with high-burden lymphoma or chronic/non-acute leukemias who require complex procedures: these trials evaluate dose-intense or combination chemotherapy delivered in the inpatient setting plus protocolized infection prophylaxis, transfusion strategies, and management of tumor lysis or marrow suppression. The patient population includes those admitted for myelosuppressive therapy or procedural interventions (e.g., central venous access, biopsies, or plasmapheresis) with major complications (MCC) that increase length of stay and resource use. Results inform clinicians and payers about inpatient resource intensity, complication rates, and short-term outcomes that drive DRG cost and reimbursement considerations.
    • Comparative effectiveness studies of alternative procedural approaches and peri-procedural risk mitigation for lymphoma/non-acute leukemia patients undergoing invasive procedures: these trials compare techniques such as image-guided biopsy, different vascular access strategies, or variations in transfusion and antimicrobial protocols to reduce procedure-related morbidity. The focus population is patients categorized under this DRG because they undergo “other procedures” and present with comorbidities or complications that qualify as MCC; endpoints include procedure-related complications, readmissions, and ICU transfers. Findings are relevant to providers and payers by identifying protocols that reduce complications, shorten hospital stay, and lower downstream costs associated with MCC events.
    • Post-discharge outcomes and care-transition trials targeting readmission prevention and functional recovery after hospitalization for lymphoma or non-acute leukemia with major complications: these studies test structured discharge planning, outpatient monitoring pathways, early hematology clinic follow-up, and symptom-management interventions to detect infection, bleeding, or treatment toxicity early. They enroll patients recently discharged after an admission coded to this DRG, especially those with prolonged index stays or significant in-hospital procedures, and measure 30–90 day readmissions, emergency visits, and patient-reported outcomes. Payers and health systems use this evidence to design care bundles that reduce readmissions and total cost-of-care while maintaining quality for a high-risk cohort.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    830-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.